Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 3/20 | 0.64 |
| ▸ | MEN1 | O00255 | 2/20 | 0.64 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.64 |
| ▸ | GABBR2 | O75899 | 3/20 | 0.62 |
| ▸ | GABBR1 | Q9UBS5 | 3/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.62 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.62 |
| ▸ | DRD3 | P35462 | 1/20 | 0.62 |
| ▸ | BLM | P54132 | 1/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | THRB | P10828 | 1/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.49 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.43 |
| ▸ | SCN4A | P35499 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL390336 | 1.00 | CYP2C9 (0.64) | CYP2C9MEN1CYP2D6CYP2C19KMT2A | |
| SCHEMBL5721009 | 1.00 | CYP2C9 (0.64) | CYP2C9MEN1CYP2D6CYP2C19KMT2A | |
| Hydrochloric Acid SCHEMBL20446442 | 0.98 | CYP2C9 (0.62) | CYP2C9MEN1CYP2D6CYP2C19KMT2A | |
| Hydrochloric Acid SCHEMBL18130542 | 0.98 | CYP2C9 (0.62) | CYP2C9MEN1CYP2D6CYP2C19KMT2A | |
| Hydrochloric Acid SCHEMBL18130541 | 0.98 | CYP2C9 (0.62) | CYP2C9MEN1CYP2D6CYP2C19KMT2A | |
| SCHEMBL29720969 | 0.98 | CYP2C9 (0.62) | CYP2C9MEN1CYP2D6CYP2C19KMT2A | |
| SCHEMBL14785618 | 0.84 | CYP2C9 (0.50) | CYP2C9MEN1CYP2D6CYP2C19KMT2A | |
| SCHEMBL390453 | 0.84 | CYP2C9 (0.50) | CYP2C9MEN1CYP2D6CYP2C19KMT2A | |
| SCHEMBL19810879 | 0.84 | CYP2C9 (0.50) | CYP2C9MEN1CYP2D6CYP2C19KMT2A | |
| SCHEMBL6965546 | 0.84 | FFAR1 (0.50) | CYP2C9MEN1CYP2D6CYP2C19KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12252495-B2 | Protein kinase B inhibitors | ASTRAZENECA AB (SE) | 2025-03-18 | — | — | US | disclosed |
| CN-118185900-B | Transaminase, preparation method and application thereof, and preparation method of amino-containing compound | 爱斯特（成都）生物制药股份有限公司 | 2024-07-30 | — | — | CN | disclosed |
| CN-118185900-A | Transaminase, preparation method and application thereof, and preparation method of amino-containing compound | 爱斯特（成都）生物制药股份有限公司 | 2024-06-14 | — | — | CN | disclosed |
| US-20240109902-A1 | PROTEIN KINASE B INHIBITORS | ASTRAZENECA AB (SE) | 2024-04-04 | — | — | US | disclosed |
| US-11760760-B2 | Protein kinase B inhibitors | ASTRAZENECA AB (SE) | 2023-09-19 | — | — | US | disclosed |
| CN-115066614-A | Biomarkers for treating cancer using MDM2 antagonists | 大冢制药株式会社 | 2022-09-16 | — | — | CN | disclosed |
| US-20220220116-A1 | PROTEIN KINASE B INHIBITORS | ASTRAZENECA AB (SE) | 2022-07-14 | — | — | US | disclosed |
| US-11236095-B2 | Protein kinase B inhibitors | ASTRAZENECA AB (SE) | 2022-02-01 | — | — | US | disclosed |
| WO-2021121276-A1 | FUSED TETRACYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | 江苏恒瑞医药股份有限公司 | 2021-06-24 | — | — | WO | disclosed |
| US-20200239483-A1 | PROTEIN KINASE B INHIBITORS | ASTRAZENECA AB (SE) | 2020-07-30 | — | — | US | disclosed |
| EP-2201012-A1 | PYRROLO [2, 3 -D] PYRIMIDIN DERIVATIVES AS PROTEIN KINASE B INHIBITORS | AstraZeneca AB (SE) | 2010-06-30 | — | — | EP | disclosed |
| US-20100125064-A1 | 3-Imidazolyl-Indoles for the Treatment of Proliferative Diseases | NOVARTIS AG (CH) | 2010-05-20 | — | — | US | disclosed |
| CN-101679382-A | 3-imidazolyl-indoles for the treatment of proliferative diseases | NOVARTIS AG | 2010-03-24 | — | — | CN | disclosed |
| EP-2142535-A2 | 3-IMIDAZOLYL-INDOLES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | Novartis Ag (CH) | 2010-01-13 | — | — | EP | disclosed |
| US-20090163524-A1 | Novel Protein Kinase B Inhibitors - 060 | ASTRAZENECA AB (SE) | 2009-06-25 | — | — | US | disclosed |
| WO-2009047563-A1 | PYRROLO [2, 3 -D] PYRIMIDIN DERIVATIVES AS PROTEIN KINASE B INHIBITORS | ASTRAZENECA AB (SE) | 2009-04-16 | — | — | WO | disclosed |
| WO-2008119741-A2 | 3-IMIDAZOLYL-INDOLES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2008-10-09 | — | — | WO | disclosed |
| EP-1028125-B1 | Dipeptide compounds having fungicidal activity and their agronomic use | ISAGRO RICERCA SRL (IT) | 2004-01-28 | — | — | EP | disclosed |
| US-6448228-B1 | FUNCTIONALIZED OLIGOPEPTIDE HAVING HIGH FUNGICIDAL ACTIVITY; ONE OR TWO ALIPHATIC AMINO ACIDS SUCH AS VALINE, LEUCINE AND ISOLEUCINE, CONJUGATED TO ONE OR TWO AROMATIC AMINO ACIDS, SUCH AS PHENYL-GLYCINE, PHENYLALANINE AND BETA-PHENYLALANINE | ISAGRO RICERCA S.R.L. (IT) | 2002-09-10 | — | — | US | disclosed |
| EP-1028125-A1 | Dipeptide compounds having fungicidal activity and their agronomic use | Isagro Ricerca S.r.l. (IT) | 2000-08-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12252495-B2 | Protein kinase B inhibitors | PRKAR2B, PRKCB, AKT1 | CYP2C9 4111/4885MEN1 613/4885CYP2D6 3865/4885 |
| US-20220220116-A1 | PROTEIN KINASE B INHIBITORS | PRKAR2B, PRKCB, AKT1 | CYP2C9 4111/4885MEN1 613/4885CYP2D6 3865/4885 |
| US-20240109902-A1 | PROTEIN KINASE B INHIBITORS | PRKAR2B, PRKCB, AKT1 | CYP2C9 4111/4885MEN1 613/4885CYP2D6 3865/4885 |
| US-20100125064-A1 | 3-Imidazolyl-Indoles for the Treatment of Proliferative Diseases | MDM4, TP53, MDM2 | CYP2C9 2441/4885MEN1 323/4885CYP2D6 1803/4885 |
| US-20090163524-A1 | Novel Protein Kinase B Inhibitors - 060 | PRKAR2B, PRKCB, MAP3K20 | CYP2C9 4553/4885MEN1 730/4885CYP2D6 4066/4885 |
| US-20200239483-A1 | PROTEIN KINASE B INHIBITORS | PRKAR2B, PRKCB, AKT1 | CYP2C9 4111/4885MEN1 613/4885CYP2D6 3865/4885 |
| US-11236095-B2 | Protein kinase B inhibitors | PRKAR2B, PRKCB, AKT1 | CYP2C9 4111/4885MEN1 613/4885CYP2D6 3865/4885 |
| US-11760760-B2 | Protein kinase B inhibitors | PRKAR2B, PRKCB, AKT1 | CYP2C9 4111/4885MEN1 613/4885CYP2D6 3865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.